Upload
others
View
5
Download
0
Embed Size (px)
Citation preview
In Vivo Predictive Dissolution – Flux
Measurements
Konstantin Tsinman, PhD
Chief Scientific Officer
Pion Inc
What do we mean by IVIVC?
FDA2:IVIVC is a predictive mathematical model describing the
relationship between an in vitro property of a dosage
form and a relevant in vivo response.
USP1:The establishment of a rational relationship between a
biological property, or a parameter derived from a
biological property produced by a dosage form, and a
physicochemical property or characteristic of the same
dosage form.
1. United States Pharmacopoeia. In vitro and In vivo Evaluations of Dosage Forms,
27th edition, Revision, Mack Publishing Co., Easton, PA., 2004.
2. Guidance for industry, extended release oral dosage forms: development,
evaluation and application of an in vitro/in vivo correlation. FDA, CDER, 1997.
FDA2:IVIVC is a predictive mathematical model describing the
relationship between an in vitro property of a dosage
form and a relevant in vivo response.
In Vitro
Property
Math.
Model
In Vivo
Response
In Vitro
Property
In Vivo
Response
The Holy Grail of in vitro assay
≈
What is Our Goal?
Chasing the Perfect Model
“Plumbing” Man“Real” Man
Small intestine of
“Absolutely
Cylindrical Man”
Looking for a Robust Predictive Model
Stomach of
“Absolutely
Cylindrical Man”
“Real” Man “Absolutely Cylindrical” Man
Absorption is related to
mass transport
of drug compound from GIT
through membranes
t
ABS dAdttimelocationGITJMass ),(
Fluxis a measure of transport:
the net number of moles of particles
crossing unit area per unit time
perpendicular to unit area
)(1
tcPdt
dc
A
V
dt
dM
AJFlux De
AA
Definition Fick’s First Law
pH
Permeability
Suppressed
Solubility
Enhanced
Flux
Unchanged
Permeability, Solubility –Excipients
Classification Gradient Map
Collaborative Effort of Pion and H. La RocheAvdeef et al. Eur J Pharm Sci. 2008;33(1):29–41; Avdeef et al. Pharm. Res., 2007, 24, 530-545;
Bendels et al. Pharm. Res. 2006, 23, 2525-2535.
pH
Permeability
Suppressed
Solubility
Enhanced
Flux
Enhanced
Permeability, Solubility –Excipients
Classification Gradient Map
Collaborative Effort of Pion and H. La RocheAvdeef et al. Eur J Pharm Sci. 2008;33(1):29–41; Avdeef et al. Pharm. Res., 2007, 24, 530-545;
Bendels et al. Pharm. Res. 2006, 23, 2525-2535.
Why Dissolution Study May Not Predict
In Vivo Data?
M. Kataoka, et al., Pharm. Res., 2012, 29, 1485-1494
Flux Studies using µFLUX™ Setup
)()( tcPdtA
dmtJFlux De
Combining benefits of in situ concentration monitoring
with parallel dissolution-permeability setup
Fiber Optic Probes
Donor
CompartmentSGF->FaSSIF
transitionReceiver
Compartment
Sink buffer
pH 7.4
Separating
Membrane
Pion GIT-PAMPA
Dissolution/Flux in FaSSIF
Research Compound
SGF – FaSSIF transformation
after 30 min of the assay
Winner formulation
performed best in dog model
Andy Z. X. Zhu, et. al. Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative
Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with
Physiologically Based Pharmacokinetic Modeling AAPS J., 2016, DOI: 10.1208/s12248-016-9972-4
Risk Assessment of pH Modifying DrugsSmall Volume Flux Measurements
1. Stewart AM et al. Development of a Biorelevant, Material-Sparing Membrane Flux Test for Rapid
Screening of Bioavailability-Enhancing Drug Product Formulations. Mol Pharm [Internet]. 2017
Jun 5;14(6):2032–46.
2. Stewart AM, et al. Impact of Drug-Rich Colloids of Itraconazole and HPMCAS on Membrane Flux in
Vitro and Oral Bioavailability in Rats. Mol Pharm [Internet]. 2017 Jul 3;14(7):2437–49.
Rela
tive M
ax A
bs
Rate
In V
ivo
Relative Flux In Vitro Fed Conditions
“Vessel-in-Vessel” Flux Setup
Relating Flux Increase In Vivo
Absorption Rate
Itraconazole
Bend Research (Lonza)
Formulations of Itraconazole1
1Tsinman et al. Ranking Itraconazole Formulations Based on the Flux through Artificial
Lipophilic Membrane. Pharm Res. 2018;35(8).
µFLUX Results (in vitro) Correlation with Rat PK data
(in vivo)
Dose Number
)()/(
)(0
mLVmLmgS
mgDoseD
GITGIT
Dissolution Number
Permeability Number
Can Flux Data Predict Absorption?
1(min ) (min)n Diss tranD k t
1(min ) (min)n Perm tranP k t
nn
a
P
D
D
F01
1exp1
Sugano K. Biopharmaceutics Modelling and Simulation. Wiley & Sons. 2012
Permeability Number
How to Capture Biorelevance for Absorption Numbers
1(min ) (min); GITn Perm tran Perm eff
GIT
AP k t k P
V
For Biorelevance
either
( ) ( )Perm Permk in vitro k in vivo
or
( ) ( )
( )
eff eff
GIT
GIT
P in vitro P in vivo
Ain vivo isused
V
How Biorelevant is Double-Sink™ PAMPA?
Avdeef et al. J Pharm Sci. 2007 96(11):2893-909.
The same membrane is used in FLUX Measurements!
For HJ Permeability
absorption rate was
measured and the
cylindrical model
was applied, i.e.𝐴𝐺𝐼𝑇𝑉𝐺𝐼𝑇
≈2
𝑅𝑆𝐼
Solubility/Permeability in FormulationDevelopability Classification System (DCS)
J. Buttler, J. Dressman. The Developability Classification System: Application of Biopharmaceutics
Concepts to Formulation Development. J. Pharm. Sci., Vol. 99, 4940–4954 (2010)
SPJFlux e Solubility Limited Cases:
DCS and Flux
)min(102.1
)(500
)()/(10
215
3
4
cmmgDose
cm
mgDosescmSPJ e
What Flux value should be a target to be Class 1 of DCS?
Assumptions:
Permeability through PAMPA membrane represents human jejunum permeability;
Flux does not change (no supersaturation/precipitation phenomenon)
Example:
Q. Projected Dose is 200 mg. What flux should we target by
changing formulations?
A. J = 1.2*200*10-5 = 2.4*10-3 mg/(min cm2) = 2.4 µg/(min cm2)
Projected Dose and Flux
Assumptions:
Permeability through PAMPA membrane represents human jejunum permeability;
Flux does not change (no supersaturation/precipitation phenomenon)
What is the Dose limit to stay DCS Class 1 for a
particular Flux value
)(103.8 4 mgJDose
Example:
Q. The measured flux for my formulation is 0.1 µg/(min cm2). What
dose would still be classified as DCS Class 1?
A. D0 = 8.3*104*0.1*10-3 = 8.3 (mg)
Estimation of the Fraction Absorbed
Solubility-Permeability Limiting Cases
0
( )SItransit
n SIa
Dose
SI
AJ T
P VF
mDV
For the Case of Absolutely Cylindrical Man
2 2; ( ) / 250( )
1.5( )SI Dose
SI SISI
A mDose mg mL
V VR cm
%43%100*4.0
21033.100045.0(max)
aF
%6.2%100*4.0
21033.1000032.0(min)
aF
Formulations of Itraconazole1
1Tsinman et al. Ranking Itraconazole Formulations Based on the Flux through Artificial
Lipophilic Membrane. Pharm Res. 2018;35(8).
Maximum and Minimum Absorbable Dose Supersaturating-Precipitating Formulations
Supersaturating
Formulation
Initial Flux
Late Flux
t
lateABS
t
initABS
dAdtJkM
dAdtJkM
min
max
FLUX
Donor Chamber Receiver Chamber
MacroFLUX to Study Final Dosage Forms
USP compatible Vessel
250 mL – 900 mL
FO Probe connected
to Rainbow
instrument
Absorption Chamber
FO Probe connected
to Rainbow
instrument
Overhead
stirrer
Separating lipophilic
membrane
BioFLUX
Bioequivalence Study for Generics
Brand and Generic Formulations of Telmisartan
N
N
N
N
OH
O
CH3
CH3
CH3
Borbás E, et al. The effect of formulation additives on in vitro dissolution-absorption profile and in vivo
bioavailability of telmisartan from brand and generic formulations. Eur J Pharm Sci. 2018;114(1):310–7.
Formulations Ingredients
LactoseSorbitol Mannitol
Predicting Risks in Bioequivalence Studies
“Normal” SGF → FaSSIFpH 1.6 – pH 6.5
pH 1.6 – pH 6.5
Type-I
“Alkalized” SGF →FaSSIF pH 4.0 – pH 6.5
pH 4.0 – pH 6.5
Type-II
Drug-Drug Interaction (Drug Products)
pH Modifying Agents
Li et al. Using pH Gradient Dissolution with In-Situ Flux Measurement to Evaluate Bioavailability and DDI for Formulated Poorly Soluble Drug Products. AAPS PharmSciTech (in publication)
Pang J, Dalziel G, Dean B, Ware JA, Salphati L. Mol Pharm. 2013;10(11):4024–31.
GDC-09411, BCS Class IIbStrong DDI Expected in Clinical Studies
• >90% reduction in flux and absorbed amount
in vitro
• ~80% reduction in AUC due to DDI of ARA in
dog PK studies
Compound C (BCS Class IIb)Product Formulated to Minimize DDI from ARA
Food Effect
To eat or not to eat…
Commercial Itraconazole Formulations
BioFLUX 250 mL
FaSSIF
FeSSIF
Brouwers J, Geboers S, Mols R, Tack J, Augustijns P. Int J Pharm. 2017;525(1):211–7.
In Vitro – In Vivo
In Vivo:Positive Food Effect for Capsules
Slight Negative for Solution
Positive
Negative
Conclusions
•Flux assays allow investigation of complex formulations and
building realistic PK predictions
•Introduction of absorption chamber into dissolution setup can
lead to more biorelevant dissolution studies
•It was demonstrated that relatively simple and robust flux
measurements can provide great in vitro tool capable of
capturing major factors related to absorption thus leading to
realistic IVIVC
•Complication of the in vitro model does not necessary mean
that better IVIVC can be achieved
Select Your “Man” Wisely
For Biorelevance Study
Acknowledgements
Oksana Tsinman
Bálint Sinko
Enikó Borbas
Zsombor K. Nagy
Larry Wigman
Jane Li
Bernd Riebesehl
Michael Juhnke
Arnaud Grandeury
Bernard Van Eerdenbrugh
Saijie Zhu